



BLA 761367

BLA APPROVAL

CSL Behring LLC
Attention: Tu Dinh Tu, PharmD
Director, Global Regulatory Affairs, Region North America
1020 First Avenue
P.O. Box 61501
King of Prussia, PA 19406-0901

Dear Dr. Tu:

Please refer to your biologics license application (BLA) received June 29, 2023, and your amendments, submitted under section 351(a) of the Public Health Service Act for Andembry (garadacimab-gxii) injection for subcutaneous use.

We acknowledge receipt of your resubmission dated December 17, 2024, which constituted a complete response to our October 7, 2024, action letter.

LICENSING

We have approved your BLA for Andembry (garadacimab-gxii) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Andembry under your existing Department of Health and Human Services U.S. License No. 1767. Andembry is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture garadacimab-gxii drug substance at CSL Behring (Australia) Pty Ltd in Broadmeadows, Australia. The (b) (4) drug product will be manufactured and filled at CSL Behring GmbH in Marburg, Germany. The final drug product will be assembled, labeled and packaged at CSL Behring GmbH in Marburg, Germany for the prefilled syringe with needle safety device or at (b) (4) (b) (4) for the prefilled autoinjector. You may label your product with the proprietary name, Andembry, and market it in 200 mg/1.2 mL solution in single-dose prefilled autoinjector and in single-dose prefilled syringe with needle safety device.

DATING PERIOD

The dating period for Andembry shall be 36 months from the date of manufacture when stored at 2°C - 8°C. The date of manufacture shall be defined as the date of final sterile

filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C.

Results of ongoing stability studies should be submitted throughout the dating period, as they become available, including the results of stability studies from the first three production lots.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Andembry to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Andembry, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* (October 2009).²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761367.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Andembry was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues in the intended population as the safety profile is similar to that of other drugs or biological products approved for HAE prophylaxis. Because there were no controversial issues that would benefit from advisory committee discussion, convening an advisory committee meeting with outside expertise was not necessary.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

POST APPROVAL FEEDBACK MEETING

New biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

If you have any questions, contact Nina Ton, Senior Regulatory Project Manager, at 301-796-1648 or phuong.ton@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Kathleen Donohue, MD
Deputy Director
Office of Immunology and Inflammation (OII)
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

KATHLEEN M DONOHUE
06/16/2025 02:16:51 PM